Healthcare
Novavax, Inc.(NVAX)
Live Price
Offline$9.13
-3.89% today
Window Change
-16.77%
Window
May 29, 2026 โ Jun 18, 2026
- Market Cap
- $1.31B
- Revenue Growth
- +64.7%
- EPS Growth
- +321.1%
- Dividend Yield
- 0.0%
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 15 bars ยท May 29, 2026 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Novavax, Inc. (NVAX) is a Healthcare stock with a market cap of $1.31B and listed on NASDAQ. The stock last traded around $9.13 and down 16.8% across the available one-year price window (May 29, 2026 โ Jun 18, 2026). Baseline metrics include revenue growth of +64.7%, EPS growth of +321.1%, a dividend yield of 0.0%. What stands out right now is revenue +64.7%, EPS +321.1%, free cash flow -149.4% with operating margin 41.3% and ROIC 64.3%. Valuation is more restrained than many high-expectation growth names at P/E 3.0 and price/sales 1.2. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines NVAX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+64.7% vs +7.6% peer median
Operating Margin
Above sector median
+41.3% vs +19.4% peer median
P/E
Below sector median
3.0 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +64.7% and EPS at +321.1%, with operating margin around 41.3%.
Benchmark Edge
NVAX vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
NVAX
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
NVAX Max Drawdown
-21.97%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for NVAX and SPY.
Company Overview
Novavax, Inc.
NASDAQ Global Select
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
- Leadership
- John Charles Jacobs
- IPO Date
- Dec 5, 1995
- Employees
- 952
- Street Address
- 21 Firstfield Road
- Mailing
- Gaithersburg, MD, 20878
- Region
- Gaithersburg, MD, US
- Reporting Currency
- USD
- Investor Line
- 240 268 2000
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 3.0
- EV/EBITDA
- 2.7
- Price/Sales
- 1.2
- Price/Book
- โ
Growth
- Revenue
- +64.7%
- EPS
- +321.1%
- Free Cash Flow
- -149.4%
Profitability
- Gross Margin
- 93.3%
- Operating Margin
- 41.3%
- Net Margin
- 39.2%
- ROE
- -546.2%
- ROIC
- 64.3%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 2.13
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.